(Received 1 October 1973) After combined pancreatic and T1 ribonuclease treatment of RNA, a characteristic series of products of the type A"N are obtained, where N can be any of the four ribonucleosides. Depending on whether phosphatase treatment is used before the addition of labelled phosphate at the 5'-terminus with bacteriophage phosphokinase, the labelled oligonucleotides obtained may or may not possess a phosphate group at the 3'-as well as the 5'-end. The behaviour of these characteristic products after electrophoresis on cellulose acetate strips followed by chromatography on polyethyleneimine-cellulose thin-layer plates was examined.
Several reports have appeared on the use of polyethyleneimine-cellulose for the one-or two-dimensional separation of both deoxyribo-and ribonucleotides (Randerath & Randerath, 1967; Southern & Mitchell, 1971; Griffin, 1971) . The compact spots obtained made the method particularly suitable for the separation of very small amounts of oligonucleotides. In the course of sequence studies of mouse globin mRNA, it was necessary to characterize the behaviour of the oligonucleotide products of a digest with pancreatic plus T1 RNAases.* Pancreatic RNAase hydrolyses internucleotide bonds in RNA specifically after cytidine and uridine residues, giving first a 2': 3'-cyclic phosphate and then in turn hydrolysing this to the 3'-phosphate. Poly(A) sequences are also hydrolysed slowly to give oligo(A) fragments by pancreatic RNAase, or by a minor contaminating enzyme activity, particularly in solutions of low ionic strength (Beers, 1960) . T, RNAase hydrolyses internucleotide bonds specifically after guanosine residues, giving oligonucleotides terminating in the 3'-phosphate. Bacterial alkaline phosphatase will hydrolyse 3'-phosphate groups (as well as 5'-phosphate groups), but will not attack 2': 3'-cyclic phosphates or phosphodiester bonds. Bacteriophage phosphokinase transfers a phosphate group from the y-position of ATP to the 5'-end of an oligonucleotide or a mononucleotide, but not to a mononucleoside. Therefore, depending on whether the terminal phosphate is cyclic or not, and whether phosphatase is used, series of oligonucleotides of the form (pA).pN-OH and (pA)"pNp will be generated after treatment of RNA with T1 plus pancreatic RNAases, where N can be any of the four ribonucleosides.
* Abbreviation: RNAase, ribonuclease. Vol. 137
Materials and Methods
Pancreatic RNAase A, poly(A,G), poly(A,C) and poly(A,U) were purchased from Sigma (London) Chemical Co., Kingston-upon-Thames, Surrey, U.K.; poly(A), poly(U) and poly(C) were from Miles Laboratories, Stoke Poges, Slough, U.K.; RNAase T, was from Sankyo Co., Tokyo, Japan; and bacterial alkaline phosphatase was from Worthington Biochemical Co., Freehold, N.J., U.S.A. Polynucleotide kinase, which was substantially RNAasefree, was a kind gift from Dr. K. Murray, Department of Molecular Biology, University ofEdinburgh, U.K., and was prepared as described by Richardson (1965 10mg/ml and bacterial alkaline phosphatase to 0.1mg/ml and incubation was carried out for a further 30min at 37°C. The reaction was terminated by the addition of KCl solution to 0.035M, followed by an equal volume of water-saturated phenolchloroform (1:1, v/v). The RNA was extracted twice and dried down.
Labelling ofoligonucleotides with phosphokinase
The digested RNA was taken up in 1 ,l of 0.1 MTris-HCl (pH 7.5)-11 mM-2-mercaptoethanol-1 1 mMMgCl2-0.27mM-[y-32P]ATP containing approx. 1 unit of polynucleotide kinase (1 unit is the amount of enzyme catalysing the formation of 1nmol of acidinsoluble 32p in 30min at 37°C). Incubation was carried out at 37°C for 45rmin (Szekely & Sanger, 1969) . The mixture was dried down under vacuum, and the 32P-labelled oligonucleotides were taken up in 0.7/s1 of dye mixture (Brownlee, 1972) and separated by using techniques based on those described by Southern & Mitchell (1971) . Separation methods The oligonucleotide mixture was applied to 47cm-long Cellogel strips equilibrated with 7M-urea-1 mM-EDTA-5 % (v/v) acetic acid, adjusted to pH4.2 with pyridine. Electrophoresis was carried out at 3kV until the pink and blue marker spots had separated by approx. 11cm, usually for 45-50min. The position of the oligonucleotides was determined with a hand monitor (from just past the pink marker dye to within 2-3cm of the origin) and they were transferred to a pre-wetted polyethyleneiminecellulose plate by using filter-paper wicks and a glass rod, a technique developed by Dr. E. M. Southern (personal communication), which gives a very thin streak and quantitative transfer. Chromatography in the second dimension was with 1.5M-formate buffer adjusted to pH3.5 with pyridine. After the solvent front had risen overnight to within a few cm of the top of the 40cm thin-layer plate, the chromatograms were dried, marked with radioactive ink and radioautographed by using Kodirex X-ray film.
Results
Poly(A,C), poly(A,G) and poly(A,U), after treatment with pancreatic and T1 RNAases give mixtures of oligo(A) fragments plus fragments with various numbers of adenosine residues terminating in cytidine, guanosine or uridine. All oligonucleotides detected are labelled with [32P]phosphate on the 5'-terminus. If phosphatase is used (Figs. la, 2a, 3a) the oligonucleotides have no phosphate on the 3'-terminus; if phosphatase is omitted there are phosphate groups on both 3'-and 5'-ends, and mononucleotides are also labelled (Figs. lb, 2b, 3b) . With poly(A) (Fig. 4) , the isopliths obtained are similar because the cyclic phosphate generated by the action of pancreatic RNAase (or some contaminant of pancreatic RNAase) is not hydrolysed to the 3'-phosphate and is therefore not susceptible to the action of bacterial alkaline phosphatase (Markham, 1957) . The small amount of (pA).pA-OH seen presumably represents the 3'-terminal fragments.
The mixture of poly(A), poly(G), poly(C) and poly(U), phosphorylated without phosphatase treatment after enzymic digestion is shown in Fig. 5 . Only the oligo(A) fragments and pCp, pGp and pUp are seen. Fig. 6 Fig. 4b) enzymic treatment and kinase labelling (but without phosphatase treatment) of a mixture of poly(A,C), poly(A,U), poly(A,G) and poly(A). The characteristic isopliths derived from poly(A) are clearly distinguishable from those terminating in cytidine, guanosine or uridine.
Discussion
Comparison of the 'fingerprints' of the oligonucleotides with and without phosphatase treatment indicates that the presence of a phosphate group on the 3'-terminus increases the mobility of the oligonucleotide in the first dimension, and (with the exception of the isopliths terminating in adenosine) decreases the mobility in the second dimension. With the exception of some overlap between the isopliths (pA),pGp and (pA),pUp, each of the oligonucleotides occupies a unique and identifiable position in the 'fingerprint'. It is apparent that the enzyme activity which hydrolyses poly(A) to oligo(A) does not break the cyclic phosphate into a phosphatasesusceptible 3'-linkage. It is also apparent that commercial poly(A) contains very small amounts of contaminating cytidine (Fig. 4b) . Because mononucleotides as well as oligonucleotides are phosphorylated if phosphatase treatment is omitted, this experimental protocol has advantages if quantitative measurement is attempted.
These techniques have been applied by us to the study of the poly(A) region of mouse globin mRNA (Mansbridge et al., 1973) . Others have used a mixture of T1 plus pancreatic RNAases to analyse the methylated base sequences in rRNA (Maden & Forbes, 1972; ) by using conventional 'fingerprinting' techniques (Brownlee, 1972) . Similar digests of Rous sarcoma virus have been separated by homochromatography (Horst et al., 1972) .
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